First Report Customer Care 
All time: 4.6

Latest / Last 30 Days: 5.0

526 Reviews

Credit Rating - SHANGHAI PHARMASCIENCES EUROPE LLP

ANALYSIS
Credit Risk Update: ACCOUNTS DUE FLAG: SHANGHAI PHARMASCIENCES EUROPE LLP, DALTON HOUSE, 60, WINDSOR AVENUE, LONDON, SW19 2RR. The legal status is a Limited Liability Partnership and the current status at the registry of companies is Active - Proposal to Strike off. The company was incorporated on 1 April 2015.

The accounts next due date is 1 January 2017. There are no mortgages.

The above was based on public record information as at 27 September 2024 and may not reflect the current status. Please access the current report to ascertain the current status and credit rating.
SUMMARY
Registered Number: OC399167
Date Incorporated: 1 April 2015
Date Latest Accounts: Unknown
BUSINESS INFORMATION
Legal Form: Limited Liability Partnership
Previous Names: None
Registered Number: OC399167
Annual Return: Unknown
Registered Office: DALTON HOUSE, 60, WINDSOR AVENUE, LONDON, SW19 2RR
SIC Code and Operations: None Supplied
SECURED CREDITORS
Number of Mortgages 0
Satisfied Mortgages 0
Part Satisfied Mortgages 0
Unsatisfied Mortgages 0
CREDIT RISK RATING
This is the credit risk assessment used by one of the top UK credit reference agencies.
Risk Score (1-100):

SHANGHAI PHARMASCIENCES EUROPE LLP

Click Here

to view this information

Risk Assessment:
Credit Rating:



First Report Score: (0-10):

Financial Status Guide:
10  trafficlight Very Strong
9   Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical
Report Created On 7 October 2024 Copyright © 2024 First Report Ltd


Recent Searches

Reg No. Reg Name Status
09233467 SHANGHAI PINXI INDUSTRIAL CO., LTD Active - Proposal to Strike off
09890922 SHANGHAI PINXING EXPLOSION-PROOF MOTOR CO., LTD Active
14928782 SHANGHAI PLUSPARK ELECTRONICS CO., LTD Active
08262586 SHANGHAI PREMIER LTD. Active
11953696 SHANGHAI PREMIUM (LONDON) LTD Active

In using this service you agree to the Terms and Conditions

© 2024 First Report Ltd